RxDoctor Payments Data

Brian Hard, MD

Neurology · Rome, GANPI 1225216864

Payments from drug & device makers

$5,502in general payments, 2019–2025

Across 314 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$477
  • UCB, Inc.$431
  • Novartis$354
  • Biogen$338
  • Pfizer$313
  • MDD US Operations, LLC$258
  • plus $3K from 44 others

What the payments were for

  • Speaking & faculty fees$631%
  • Food & beverage$5,32597%
  • Education$1132%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,502 in reported general payments places this provider in the 65th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$217,982
Medicare patients
767
Services billed
12,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab19$164,054
Aimovig AutoinjectorErenumab-Aooe179$142,120
AustedoDeutetrabenazine18$116,866
VumerityDiroximel Fumarate12$103,600
IngrezzaValbenazine Tosylate12$86,444
Nurtec OdtRimegepant Sulfate63$81,118
UbrelvyUbrogepant56$61,278
Emgality PenGalcanezumab-Gnlm64$55,460
QuliptaAtogepant28$36,279
XcopriCenobamate26$27,543
RytaryCarbidopa/Levodopa48$23,235
Ajovy AutoinjectorFremanezumab-Vfrm21$22,862
NeuproRotigotine22$17,912
Dalfampridine ErDalfampridine33$14,965
Levetiracetam422$13,889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$166$116,86618 claims
AbbVieUbrelvy, Qulipta, Namzaric$477$110,08498 claims
BiogenVumerity$338$103,60012 claims
PfizerNurtec Odt, Dilantin$313$89,05793 claims
Neurocrine Biosciences, Inc.Ingrezza$152$86,44412 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$77$32,575120 claims
SK Life Science, Inc.Xcopri$64$27,54326 claims
UCB, Inc.Neupro$431$17,91222 claims
Upsher-smith Laboratories LLCTopiramate$102$2,994308 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 506 neurology providers in Georgia.

Other neurology in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →